Background and Need for Legislation
Recent estimates indicate that about 35,000 people in the
United States are living with amyotrophic lateral sclerosis
(ALS) and there are more than 5,000 new cases diagnosed each
year.\1\
---------------------------------------------------------------------------
\1\Ctrs. for Disease Control and Prevention (CDC), National
Amyotrophic Lateral Sclerosis (ALS) Registry, About the National ALS
Registry (May 4, 2026), https://www.cdc.gov/als/abouttheregistrymain/
index.html.
---------------------------------------------------------------------------
ALS, also known as Lou Gehrig's disease, is a degenerative
neurological condition that affects the function of motor
neurons, or nerve cells in the brain and spinal cord, that
control voluntary muscle movement and breathing.\2\ Early signs
and symptoms of the disease include, but are not limited to,
difficulty chewing or swallowing, slurred speech, tight and
stiff muscles, as well as muscular twitching, weakness, and
cramping.\3\ Throughout the disease progression, muscle
weakness and atrophy spread to other areas of the body, causing
people with ALS to experience further difficulty with forming
words and speaking, breathing, and maintaining a healthy
weight, among other symptoms.\4\ Roughly 10 percent of ALS
cases are genetic, while the rest are considered sporadic.\5\
Most individuals only survive 2 to 5 years post-diagnosis,
though progression varies.\6\
---------------------------------------------------------------------------
\2\Nat'l Insts. of Neurological Disorders and Stroke, Amyotrophic
Lateral Sclerosis (ALS), (Mar. 13, 2026), https://www.ninds.nih.gov/
health-information/disorders/amyotrophic-
lateral-sclerosis-als.
\3\Id.
\4\Id.
\5\Id.
\6\Government Accountability Office (GAO), Rare Diseases: Funding
for Rare Neurodegenerative Disease Research and Access to ALS
Investigational Drugs, GAO-26-107691 at 7 (Feb. 4, 2026), https://
www.gao.gov/products/gao-26-107691.
---------------------------------------------------------------------------
On average, it takes between 10 to 16 months to diagnose
ALS after the onset of symptoms.\7\ Accordingly, many
individuals with ALS are ineligible to participate in clinical
trials for investigational drugs due to those delays in
diagnosis and the rapid progression of the disease.\8\ There is
currently no cure for ALS.\9\
---------------------------------------------------------------------------
\7\Id. at 8.
\8\Id.
\9\GAO, supra note 6 at 1.
---------------------------------------------------------------------------
In December 2021, the ACT for ALS Act was signed into law.
Since then, it has supported research and development for
therapies for ALS and other rare neurodegenerative conditions.
The legislation aimed to improve access to therapies for
individuals with ALS and other rare neurodegenerative diseases.
To this end, the bill established a public-private partnership
for rare neurodegenerative disease research and grant programs,
through which sponsors of investigational interventions and
public and private entities could be awarded grants to support
research and development of interventions, patient access to
investigational ALS therapies, and agreements to advance the
understanding of neurodegenerative diseases.\10\ Congress
allocated funding for these three programs to the Food and Drug
Administration (FDA) and the National Institutes of Health
(NIH) through the annual Congressional appropriations process.
The Act for ALS Act will expire on September 30, 2026.
---------------------------------------------------------------------------
\10\Accelerating Access to Critical Therapies for ALS Act, Pub. L.
No. 117-79, 135 Stat. 1533, (2021).
---------------------------------------------------------------------------
Committee Action
On April 15, 2026, the Subcommittee on Health held a
legislative hearing on H.R. 8205. The title of the hearing was
``Healthier America: Legislative Proposals to Improve Public
Health.'' The Subcommittee received testimony from:
Jamie Ulmer, MA, President and CEO,
Healthcare Network;
Rachel F. Brem, MD, FACR, FSBI, Co-Founder,
Chief Medical Officer, Brem Foundation to Defeat Breast
Cancer and Professor and Vice-Chair Emeritus, The
George Washington University;
Holly Ahern, MS, MT (ASCP), Associate
Professor of Microbiology, State University of New York
Adirondack;
Amy L. Ronneberg, MBA, Chief Executive
Officer, National Marrow Donor Program;
Brian Wallach & Sandra Abrevaya, Co-
Founders, I AM ALS; and
Rene Qashie, JD, Vice President, Digital
Health, Consumer Technology Association.
On May 13, 2026, the Subcommittee on Health met in open
markup session and forwarded H.R. 8205, as amended, to the full
Committee by a voice vote.
On May 21, 2026, the full Committee on Energy and Commerce
met in open markup session and ordered H.R. 8205, as amended,
favorably reported to the House by a record vote of 46 yeas and
0 nays.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to
reauthorize and make changes to the grant award authority,
expanded access program, and public-private partnership for
research on therapies for ALS and other neurodegenerative
diseases.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 8205 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 8205:
On April 15, 2026, the Subcommittee on
Health held a legislative hearing on H.R. 8205. The
title of the hearing was ``Healthier America:
Legislative Proposals to Improve Public Health.'' The
Subcommittee received testimony from:
Jamie Ulmer, MA, President and
Chief Executive, Healthcare Network;
Rachel F. Brem, MD, FACR, FSBI,
Co-Founder, Chief Medical Officer, Brem
Foundation to Defeat Breast Cancer and
Professor and Vice-Chair Emeritus, The George
Washington University;
Holly Ahern, MS, MT (ASCP),
Associate Professor of Microbiology, State
University of New York Adirondack;
Amy L. Ronneberg, MBA, Chief
Executive Officer, National Marrow Donor
Program;
Brian Wallach & Sandra Abrevaya,
Co-Founders, I AM ALS; and
Rene Quashie, JD, Vice
President, Digital Health, Consumer Technology
Association.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 8205 contains no earmarks, limited
tax benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides for a short title of ``Accelerating
Access to Critical Therapies for ALS Reauthorization Act of
2026.''
Section 2. Reauthorization of Accelerating Access to Critical Therapies
for ALS Act
Section 2 reauthorizes the Accelerating Access to Critical
Therapies for ALS Reauthorization Act through 2031.
Section 3. Improvements to program for grants for research on therapies
for ALS
Section 3 amends the ALS grant program to improve the
requirements for participation. authorizes It requires the
Secretary of Health and Human Services to request from the
manufacturer or sponsor of an investigational drug certain data
related to enrollment, safety, and efficacy, for the purpose of
reviewing an application for renewal of a grant awarded under
this section. It also requires entities seeking a grant to
report any new and serious adverse events and patient safety
data related to its phase 3 clinical trials if considered
unexpected. Finally, this section clarifies that combined phase
2/3 clinical trials that begin enrollment within a
predetermined timeframe may be considered eligible clinical
trials under this section.
Section 4. FDA rare neurodegenerative disease action plan
Section 4 directs FDA to publish, not later than 18 months
after the date of enactment, an action plan describing
activities the agency intends to take during the 5 years after
the plan's publication to implement program enhancements,
policy development, regulatory science, and other initiatives
to facilitate the development of and access to investigations
drugs for ALS and other rare neurodegenerative diseases. This
section also directs FDA to publish a report, not later than 5
years after the date of enactment, that describes actions taken
to carry out the action plan.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
ACCELERATING ACCESS TO CRITICAL THERAPIES FOR ALS ACT
* * * * * * *
SEC. 2. GRANTS FOR RESEARCH ON THERAPIES FOR ALS.
(a) In General.--The Secretary of Health and Human Services
(referred to in this section as the ``Secretary'') shall award
grants to participating entities for purposes of scientific
research utilizing data from expanded access to investigational
drugs for individuals who are not otherwise eligible for
clinical trials for the prevention, diagnosis, mitigation,
treatment, or cure of amyotrophic lateral sclerosis. In the
case of a participating entity seeking such a grant, an
expanded access request must be submitted, and allowed to
proceed by the Secretary, under section 561 of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb) and part 312 of
title 21, Code of Federal Regulations (or any successor
regulations), before the application for such grant is
submitted.
(b) Application.--
(1) In general.--A participating entity seeking a
grant under this section shall submit to the Secretary
an application at such time, in such manner, and
containing such information as the Secretary shall
specify.
(2) Use of data.--An application submitted under
paragraph (1) shall include a description of how data
generated through an expanded access request under
section 561 of the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 360bbb) with respect to the investigational
drug involved will be used to support research or
development related to the prevention, diagnosis,
mitigation, treatment, or cure of amyotrophic lateral
sclerosis.
(3) Noninterference with clinical trials.--An
application submitted under paragraph (1) shall include
a description of how the proposed expanded access
program will be designed so as not to interfere with
patient enrollment in ongoing clinical trials for
investigational therapies for the prevention,
diagnosis, mitigation, treatment, or cure of
amyotrophic lateral sclerosis.
(4) Renewal of grants for research on therapies for
als review.--In reviewing applications for renewals of
a grant awarded under this section with respect to an
investigational drug, the Secretary shall request from
the manufacturer or sponsor, and assess, the
enrollment, safety, and any available efficacy data
relating to the investigational drug in the prevention,
diagnosis, mitigation, treatment, or cure of
amyotrophic lateral sclerosis.
(c) Selection.--Consistent with sections 406 and 492 of the
Public Health Service Act (42 U.S.C. 284a, 289a), the Secretary
shall, in determining whether to award a grant under this
section, confirm that--
(1) such grant will be used to support a scientific
research objective relating to the prevention,
diagnosis, mitigation, treatment, or cure of
amyotrophic lateral sclerosis (as described in
subsection (a));
(2) such grant shall not have the effect of
diminishing eligibility for, or impeding enrollment of,
ongoing clinical trials for the prevention, diagnosis,
mitigation, treatment, or cure of amyotrophic lateral
sclerosis by determining that individuals who receive
expanded access to investigational drugs through such a
grant are not eligible for enrollment in--
(A) ongoing clinical trials that are
registered on ClinicalTrials.gov (or successor
website), with respect to a drug for the
prevention, diagnosis, mitigation, treatment,
or cure of amyotrophic lateral sclerosis; or
(B) clinical trials for the prevention,
diagnosis, mitigation, treatment, or cure of
amyotrophic lateral sclerosis for which an
exemption under section 505(i) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 355(i))
has been granted by the Food and Drug
Administration and which are expected to begin
enrollment within one year; [and]
(3) the resulting project funded by such grant will
allow for equitable access to investigational drugs by
minority and underserved populations[.]; and
(4) the entity seeking such grant will promptly
report any new and serious adverse events and safety
information that is considered to be unexpected with
respect to the phase 3 trial to the grant-making
institution, in addition to complying with the safety
reporting requirements under section 312.32 of title
21, Code of Federal Regulations (or any successor
regulations).
(d) Use of Funds.--A participating entity shall use funds
received through the grant--
(1) to pay the manufacturer or sponsor for the direct
costs of the investigational drug, as authorized under
section 312.8(d) of title 21, Code of Federal
Regulations (or successor regulations), to prevent,
diagnose, mitigate, treat, or cure amyotrophic lateral
sclerosis that is the subject of an expanded access
request described in subsection (a), if such costs are
justified as part of peer review of the grant;
(2) for the entity's direct costs incurred in
providing such drug consistent with the research
mission of the grant; or
(3) for the direct and indirect costs of the entity
in conducting research with respect to such drug.
(e) Definitions.--In this section:
(1) The term ``participating entity'' means a
participating clinical trial site or sites sponsored by
a small business concern (as defined in section 3(a) of
the Small Business Act (15 U.S.C. 632(a))) that is the
sponsor of a drug that is the subject of an
investigational new drug application under section
505(i) of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 355(i)) to prevent, diagnose, mitigate, treat,
or cure amyotrophic lateral sclerosis.
(2) The term ``participating clinical trial'' means a
phase 3 clinical trial conducted pursuant to an
exemption under section 505(i) of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 355(i)) or section
351(a) of the Public Health Service Act (42 U.S.C.
262(a)) to investigate a drug intended to prevent,
diagnose, mitigate, treat, or cure amyotrophic lateral
sclerosis.
(3) The term ``participating clinical trial site''
means a health care facility, or network of facilities,
at which patients participating in a participating
clinical trial receive an investigational drug through
such trial.
(4) The term ``phase 3'', with respect to a clinical
trial, includes a phase 2/3 combined trial that begins
enrollment within a timeframe, determined by the
Secretary through the terms and conditions of the grant
awarded under this section.
(f) Sunset.--The Secretary may not award grants under this
section on or after September 30, [2026] 2031.
* * * * * * *
SEC. 4. [ALS AND OTHER RARE NEURODEGENERATIVE DISEASE ACTION PLAN] FDA
RARE NEURODEGENERATIVE DISEASE ACTION PLAN.
(a) In General.--Not later than 6 months after the date of
enactment of this Act, the Commissioner of Food and Drugs shall
publish on the website of the Food and Drug Administration an
action plan describing actions the Food and Drug Administration
intends to take during the 5-year period following publication
of the plan with respect to program enhancements, policy
development, regulatory science initiatives, and other
appropriate initiatives to--
(1) foster the development of safe and effective
drugs that improve or extend, or both, the lives of
people living with amyotrophic lateral sclerosis and
other rare neurodegenerative diseases; and
(2) facilitate access to investigational drugs for
amyotrophic lateral sclerosis and other rare
neurodegenerative diseases.
(b) Contents.--The initial action plan published under
subsection (a) shall--
(1) identify appropriate representation from within
the Food and Drug Administration to be responsible for
implementation of such action plan;
(2) include elements to facilitate--
(A) interactions and collaboration between
the Food and Drug Administration, including the
review centers thereof, and stakeholders
including patients, sponsors, and the external
biomedical research community;
(B) consideration of cross-cutting clinical
and regulatory policy issues, including
consistency of regulatory advice and
decisionmaking;
(C) identification of key regulatory science
and policy issues critical to advancing
development of safe and effective drugs; and
(D) enhancement of collaboration and
engagement of the relevant centers and offices
of the Food and Drug Administration with other
operating divisions within the Department of
Health and Human Services, the Partnership, and
the broader neurodegenerative disease
community; and
(3) be subject to revision, as determined appropriate
by the Secretary of Health and Human Services.
(c) FDA Rare Neurodegenerative Disease Action Plan.--
(1) In general.--Not later than 18 months after the
date of enactment of the Accelerating Access to
Critical Therapies for ALS Reauthorization Act of 2026,
the Commissioner of Food and Drugs shall publish on the
website of the Food and Drug Administration an action
plan that includes a description of the actions that
the Food and Drug Administration intends to take during
the 5-year period following publication of the action
plan with respect to the program enhancements, policy
development, regulatory science initiatives, and other
appropriate initiatives described in subsection (a).
(2) Report.--Not later than 5 years after the date of
enactment of the Accelerating Access to Critical
Therapies for ALS Reauthorization Act of 2026, the
Commissioner of Food and Drugs shall publish on the
website of the Food and Drug Administration a report
that describes the actions taken by the Food and Drug
Administration under the action plan published under
paragraph (1) and the extent to which such action plan
meets the requirements specified in paragraph (1).
* * * * * * *
SEC. 7. AUTHORIZATION OF APPROPRIATIONS.
For purposes of carrying out this Act, there are authorized
to be appropriated $100,000,000 for each of fiscal years 2022
through [2026] 2031.
[all]